BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Joosten SC, Smits KM, Aarts MJ, Melotte V, Koch A, Tjan-heijnen VC, van Engeland M. Epigenetics in renal cell cancer: mechanisms and clinical applications. Nat Rev Urol 2018;15:430-51. [DOI: 10.1038/s41585-018-0023-z] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Li B, Shi X. Key Prognostic Value of Lysosomal Protein Transmembrane 5 in Kidney Renal Clear Cell Carcinoma. IJGM 2022;Volume 15:2515-27. [DOI: 10.2147/ijgm.s357013] [Reference Citation Analysis]
2 Zhang D, Wang Y, Hu X. Identification and Comprehensive Validation of a DNA Methylation-Driven Gene-Based Prognostic Model for Clear Cell Renal Cell Carcinoma. DNA Cell Biol 2020;39:1799-812. [PMID: 32716214 DOI: 10.1089/dna.2020.5601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lommen K, Vaes N, Aarts MJ, van Roermund JG, Schouten LJ, Oosterwijk E, Melotte V, Tjan-heijnen VC, van Engeland M, Smits KM. Diagnostic DNA Methylation Biomarkers for Renal Cell Carcinoma: A Systematic Review. European Urology Oncology 2021;4:215-26. [DOI: 10.1016/j.euo.2019.07.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
4 Li Q, Zhang Z, Fan Y, Zhang Q. Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications. Front Genet 2020;11:562868. [PMID: 33510766 DOI: 10.3389/fgene.2020.562868] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Xu B, Peng Y, Ma B, Cheng S. Aberrant methylation of the 16q23.1 tumor suppressor gene ADAMTS18 promotes tumorigenesis and progression of clear cell renal cell carcinoma. Genes Genom 2021;43:123-31. [DOI: 10.1007/s13258-021-01036-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Goldsamt A, Damayanti NP, De Nigris F, Pili R. Epigenetic Dysregulation in Advanced Kidney Cancer: Opportunities for Therapeutic Interventions. Cancer J 2020;26:399-406. [DOI: 10.1097/ppo.0000000000000479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Fries JWU. MicroRNAs as markers to monitor endothelin-1 signalling and potential treatment in renal disease: Carcinoma - proteinuric damage - toxicity. Biol Cell 2019;111:169-86. [PMID: 30866090 DOI: 10.1111/boc.201800059] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Gan Y, Cao C, Li A, Song H, Kuang G, Ma B, Zhang Q, Zhang Q. Silencing of the TRIM58 Gene by Aberrant Promoter Methylation is Associated with a Poor Patient Outcome and Promotes Cell Proliferation and Migration in Clear Cell Renal Cell Carcinoma. Front Mol Biosci 2021;8:655126. [PMID: 33816562 DOI: 10.3389/fmolb.2021.655126] [Reference Citation Analysis]
9 Braga EA, Fridman MV, Loginov VI, Dmitriev AA, Morozov SG. Molecular Mechanisms in Clear Cell Renal Cell Carcinoma: Role of miRNAs and Hypermethylated miRNA Genes in Crucial Oncogenic Pathways and Processes. Front Genet 2019;10:320. [PMID: 31110513 DOI: 10.3389/fgene.2019.00320] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 10.7] [Reference Citation Analysis]
10 Tsai MF, Chen SM, Ong AZ, Chung YH, Chen PN, Hsieh YH, Kang YT, Hsu LS. Shikonin Induced Program Cell Death through Generation of Reactive Oxygen Species in Renal Cancer Cells. Antioxidants (Basel) 2021;10:1831. [PMID: 34829701 DOI: 10.3390/antiox10111831] [Reference Citation Analysis]
11 Song J, Song F, Liu K, Zhang W, Luo R, Tang Y, Ran L. Multi-omics analysis reveals epithelial-mesenchymal transition-related gene FOXM1 as a novel prognostic biomarker in clear cell renal carcinoma. Aging (Albany NY) 2019;11:10316-37. [PMID: 31743108 DOI: 10.18632/aging.102459] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
12 Feng C, Huang X, Li X, Mao J. The Roles of Base Modifications in Kidney Cancer. Front Oncol 2020;10:580018. [PMID: 33282735 DOI: 10.3389/fonc.2020.580018] [Reference Citation Analysis]
13 Zhang ZY, Zhang SL, Chen HL, Mao YQ, Li ZM, Kong CY, Han B, Zhang J, Chen YH, Xue W, Zhai W, Wang LS. The up-regulation of NDRG1 by HIF counteracts the cancer-promoting effect of HIF in VHL-deficient clear cell renal cell carcinoma. Cell Prolif 2020;53:e12853. [PMID: 32537867 DOI: 10.1111/cpr.12853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
14 Lai Y, Zeng T, Liang X, Wu W, Zhong F, Wu W. Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy. Cancer Cell Int 2019;19:221. [PMID: 31462894 DOI: 10.1186/s12935-019-0939-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
15 Incorvaia L, Madonia G, Corsini LR, Cucinella A, Brando C, Gagliardo C, Santoni M, Fanale D, Inno A, Fazio I, Foti G, Galia M, Badalamenti G, Bazan V, Russo A, Gori S. Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors. Crit Rev Oncol Hematol 2021;163:103390. [PMID: 34090998 DOI: 10.1016/j.critrevonc.2021.103390] [Reference Citation Analysis]
16 Lobo J, Jerónimo C, Henrique R. Targeting the Immune system and Epigenetic Landscape of Urological Tumors. Int J Mol Sci 2020;21:E829. [PMID: 32012885 DOI: 10.3390/ijms21030829] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
17 Xue C, Cai X, Jia J. Long Non-coding RNA Double Homeobox A Pseudogene 8: A Novel Oncogenic Propellant in Human Cancer. Front Cell Dev Biol 2021;9:709069. [PMID: 34631702 DOI: 10.3389/fcell.2021.709069] [Reference Citation Analysis]
18 Joosten SC, Odeh SNO, Koch A, Buekers N, Aarts MJB, Baldewijns MMLL, Van Neste L, van Kuijk S, Schouten LJ, van den Brandt PA, Tjan-Heijnen VC, van Engeland M, Smits KM. Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers. Clin Epigenetics 2021;13:103. [PMID: 33947447 DOI: 10.1186/s13148-021-01084-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Tong X, Xu L, Rong R, Su X, Xiang T, Peng W, Shi T. Epigenetic silencing of ZBTB28 promotes renal cell carcinogenesis. Asia Pac J Clin Oncol 2021. [PMID: 34161675 DOI: 10.1111/ajco.13560] [Reference Citation Analysis]
20 Serth J, Peters I, Hill B, Hübscher T, Hennenlotter J, Klintschar M, Kuczyk MA. Age-Related DNA Methylation in Normal Kidney Tissue Identifies Epigenetic Cancer Risk Susceptibility Loci in the ANKRD34B and ZIC1 Genes. Int J Mol Sci 2022;23:5327. [PMID: 35628134 DOI: 10.3390/ijms23105327] [Reference Citation Analysis]
21 Albiñana V, Gallardo-Vara E, de Rojas-P I, Recio-Poveda L, Aguado T, Canto-Cano A, Aguirre DT, Serra MM, González-Peramato P, Martínez-Piñeiro L, Cuesta AM, Botella LM. Targeting β2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel-Lindau Disease. J Clin Med 2020;9:E2740. [PMID: 32854260 DOI: 10.3390/jcm9092740] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Liu H, Yang Y. Identification of Mast Cell-Based Molecular Subtypes and a Predictive Signature in Clear Cell Renal Cell Carcinoma. Front Mol Biosci 2021;8:719982. [PMID: 34646862 DOI: 10.3389/fmolb.2021.719982] [Reference Citation Analysis]
23 González-Del-Alba A, Arranz JÁ, Bellmunt J, Maroto JP, Fernández-Calvo O, Valderrama BP, González-Billalabeitia E, Méndez-Vidal MJ, Cassinello J, Romero-Laorden N, Climent MÁ, Puente J, Peláez I, Lázaro-Quintela M, Gallardo E, Suárez C. Latest progress in molecular biology and treatment in genitourinary tumours. Clin Transl Oncol 2020;22:2175-95. [PMID: 32440915 DOI: 10.1007/s12094-020-02373-z] [Reference Citation Analysis]
24 Najafi M, Majidpoor J, Toolee H, Mortezaee K. The current knowledge concerning solid cancer and therapy. J Biochem Mol Toxicol 2021;:e22900. [PMID: 34462987 DOI: 10.1002/jbt.22900] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Peng S, Zhang J, Tan X, Huang Y, Xu J, Silk N, Zhang D, Liu Q, Jiang J. The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma. Front Endocrinol (Lausanne) 2020;11:586857. [PMID: 33329393 DOI: 10.3389/fendo.2020.586857] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
26 Bruckschen F, Gerharz CD, Sagir A. Renal cell carcinoma with unusual metachronous metastasis up to 22 years after nephrectomy: two case reports. J Med Case Rep 2021;15:490. [PMID: 34607612 DOI: 10.1186/s13256-021-03098-5] [Reference Citation Analysis]
27 Tan Y, Li B, Peng F, Gong G, Li N. Integrative Analysis of Sirtuins and Their Prognostic Significance in Clear Cell Renal Cell Carcinoma. Front Oncol 2020;10:218. [PMID: 32158696 DOI: 10.3389/fonc.2020.00218] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
28 Lu L, Li Y, Wen H, Feng C. Overexpression of miR-15b Promotes Resistance to Sunitinib in Renal Cell Carcinoma. J Cancer 2019;10:3389-96. [PMID: 31293642 DOI: 10.7150/jca.31676] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
29 Xiang W, Han L, Mo G, Lin L, Yu X, Chen S, Gao T, Huang C. MicroRNA-96 is a potential tumor repressor by inhibiting NPTX2 in renal cell carcinoma. J Cell Biochem 2020;121:1504-13. [PMID: 31498486 DOI: 10.1002/jcb.29385] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
30 Jarrell DK, Lennon ML, Jacot JG. Epigenetics and Mechanobiology in Heart Development and Congenital Heart Disease. Diseases 2019;7:E52. [PMID: 31480510 DOI: 10.3390/diseases7030052] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
31 Zhu Z, Ji X, Zhu W, Cai T, Xu C, Huang C, He S, Gong Y, Li X, Lin J, Zhou L. Comprehensive bioinformatics analyses of APOBECs family and identification of APOBEC3D as the unfavorable prognostic biomarker in clear cell renal cell carcinoma. J Cancer 2021;12:7101-10. [PMID: 34729111 DOI: 10.7150/jca.61972] [Reference Citation Analysis]
32 Millet-Boureima C, He S, Le TBU, Gamberi C. Modeling Neoplastic Growth in Renal Cell Carcinoma and Polycystic Kidney Disease. Int J Mol Sci 2021;22:3918. [PMID: 33920158 DOI: 10.3390/ijms22083918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Chakraborty A, Ghosh S, Biswas B, Pramanik S, Nriagu J, Bhowmick S. Epigenetic modifications from arsenic exposure: A comprehensive review. Sci Total Environ 2021;:151218. [PMID: 34717984 DOI: 10.1016/j.scitotenv.2021.151218] [Reference Citation Analysis]
34 Zhang Z, Tang Y, Liu Y, Zhuang H, Lin E, Xie L, Feng X, Tian K, Zeng J, Liu J, Yu Y. A Novel Immune-Related lncRNA-Based Model for Survival Prediction in Clear Cell Renal Cell Carcinoma. J Immunol Res 2021;2021:9921466. [PMID: 34368371 DOI: 10.1155/2021/9921466] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
35 Incorvaia L, Fanale D, Badalamenti G, Brando C, Bono M, De Luca I, Algeri L, Bonasera A, Corsini LR, Scurria S, Iovanna JL, Russo A, Bazan V. A "Lymphocyte MicroRNA Signature" as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming. Cancers (Basel) 2020;12:E3396. [PMID: 33207823 DOI: 10.3390/cancers12113396] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
36 Ingrosso D, Perna AF. DNA Methylation Dysfunction in Chronic Kidney Disease. Genes (Basel) 2020;11:E811. [PMID: 32708735 DOI: 10.3390/genes11070811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Wang J, Yin X, He W, Xue W, Zhang J, Huang Y. SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis. Acta Pharm Sin B 2021;11:406-19. [PMID: 33643820 DOI: 10.1016/j.apsb.2020.09.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 19.0] [Reference Citation Analysis]
38 Zhu J, Huang Q, Peng X, Luo C, Liu S, Liu Z, Wu X, Luo H. Identification of LncRNA Prognostic Signature Associated With Genomic Instability in Pancreatic Adenocarcinoma. Front Oncol 2022;12:799475. [PMID: 35433487 DOI: 10.3389/fonc.2022.799475] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Angulo JC, Manini C, López JI, Pueyo A, Colás B, Ropero S. The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments. Cancers (Basel) 2021;13:2071. [PMID: 33922974 DOI: 10.3390/cancers13092071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
40 Wang S, Xiang T, Yu L, Wen J, Liu F, Yang D, Wu W, Hu L. Novel Molecular Subtypes and Related Score Based on Histone Acetylation Modification in Renal Clear Cell Carcinoma. Front Cell Dev Biol 2021;9:668810. [PMID: 34631694 DOI: 10.3389/fcell.2021.668810] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Yang W, Zhang K, Li L, Xu Y, Ma K, Xie H, Zhou J, Cai L, Gong Y, Gong K. Downregulation of lncRNA ZNF582-AS1 due to DNA hypermethylation promotes clear cell renal cell carcinoma growth and metastasis by regulating the N(6)-methyladenosine modification of MT-RNR1. J Exp Clin Cancer Res 2021;40:92. [PMID: 33691743 DOI: 10.1186/s13046-021-01889-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
42 Dzulko M, Pons M, Henke A, Schneider G, Krämer OH. The PP2A subunit PR130 is a key regulator of cell development and oncogenic transformation. Biochim Biophys Acta Rev Cancer 2020;1874:188453. [PMID: 33068647 DOI: 10.1016/j.bbcan.2020.188453] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Wang Q, Xu J, Xiong Z, Xu T, Liu J, Liu Y, Chen J, Shi J, Shou Y, Yue C, Liu D, Liang H, Yang H, Yang X, Zhang X. CENPA promotes clear cell renal cell carcinoma progression and metastasis via Wnt/β-catenin signaling pathway. J Transl Med 2021;19:417. [PMID: 34627268 DOI: 10.1186/s12967-021-03087-8] [Reference Citation Analysis]
44 Chen YC, Hsu PY, Hsiao CC, Lin MC. Epigenetics: A Potential Mechanism Involved in the Pathogenesis of Various Adverse Consequences of Obstructive Sleep Apnea. Int J Mol Sci 2019;20:E2937. [PMID: 31208080 DOI: 10.3390/ijms20122937] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
45 Zheng D, Zhang Y, Xia Y, Cheng F. A Novel Gene Signature of Tripartite Motif Family for Predicting the Prognosis in Kidney Renal Clear Cell Carcinoma and Its Association With Immune Cell Infiltration. Front Oncol 2022;12:840410. [DOI: 10.3389/fonc.2022.840410] [Reference Citation Analysis]
46 Li X, Liu Z, Xia C, Yan K, Fang Z, Fan Y. SETD8 stabilized by USP17 epigenetically activates SREBP1 pathway to drive lipogenesis and oncogenesis of ccRCC. Cancer Lett 2021;527:150-63. [PMID: 34942305 DOI: 10.1016/j.canlet.2021.12.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Marigliano C, Badia S, Bellini D, Rengo M, Caruso D, Tito C, Miglietta S, Palleschi G, Pastore AL, Carbone A, Fazi F, Petrozza V, Laghi A. Radiogenomics in Clear Cell Renal Cell Carcinoma: Correlations Between Advanced CT Imaging (Texture Analysis) and MicroRNAs Expression. Technol Cancer Res Treat 2019;18:1533033819878458. [PMID: 31564221 DOI: 10.1177/1533033819878458] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Wang J, Wang C, Xu P, Li X, Lu Y, Jin D, Yin X, Jiang H, Huang J, Xiong H, Ye F, Jin J, Chen Y, Xie Y, Chen Z, Ding H, Zhang H, Liu R, Jiang H, Chen K, Yao Z, Luo C, Huang Y, Zhang Y, Zhang J. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Theranostics 2021;11:5387-403. [PMID: 33859753 DOI: 10.7150/thno.42345] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
49 Zhang ZY, Zhang SL, Chen HL, Mao YQ, Kong CY, Li ZM, Wang LS, Ma M, Han B. Low EGR1 expression predicts poor prognosis in clear cell renal cell carcinoma. Pathol Res Pract 2021;228:153666. [PMID: 34749216 DOI: 10.1016/j.prp.2021.153666] [Reference Citation Analysis]
50 Mallikarjuna P, Zhou Y, Landström M. The Synergistic Cooperation between TGF-β and Hypoxia in Cancer and Fibrosis. Biomolecules 2022;12:635. [DOI: 10.3390/biom12050635] [Reference Citation Analysis]
51 Xing XL, Liu Y, Liu J, Zhou H, Zhang H, Zuo Q, Bu P, Duan T, Zhou Y, Xiao Z. Comprehensive Analysis of Ferroptosis- and Immune-Related Signatures to Improve the Prognosis and Diagnosis of Kidney Renal Clear Cell Carcinoma. Front Immunol 2022;13:851312. [PMID: 35619698 DOI: 10.3389/fimmu.2022.851312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Zeng X, Chen K, Li L, Tian J, Ruan W, Hu Z, Peng D, Chen Z. Epigenetic activation of RBM15 promotes clear cell renal cell carcinoma growth, metastasis and macrophage infiltration by regulating the m6A modification of CXCL11. Free Radical Biology and Medicine 2022. [DOI: 10.1016/j.freeradbiomed.2022.03.031] [Reference Citation Analysis]
53 Liu Z, Tian J, Peng F, Wang J. Hypermethylation of mitochondrial DNA facilitates bone metastasis of renal cell carcinoma. J Cancer 2022;13:304-12. [PMID: 34976191 DOI: 10.7150/jca.62278] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]